A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation
injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the
tumor cells are actively growing. The investigators will do these two tests and see which one
Patients will remain on study until the completion of either the MRI perfusion or PET/CT that
are within 12 weeks of each other. After one of these scans, the patient will have no active
interventions and will be off study.
Optional: Restriction Spectrum Imaging (RSI) Sequence RSI sequence is an advanced way of
looking at your brain. The scan allows doctors to see how water is moving within brain tumors
or within brain cells. The extra sequence takes additional 4-5 minutes in the scanner. The
RSI sequence is optional. The patient will only be asked to participate if the doctor
believes that it will be helpful.
Off study: Patients will remain on study until the completion of either the MRI perfusion or
PET/CT that are within 12 weeks of each other. After one of these scans, the patient will
have no active interventions and will be off study. Patients will obtain a standard of care
brain MRI scan about every 2-3 months. These MRI scans will be used to track disease
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
18 Years and Over
More Inclusion & Exclusion Criteria
- Pathological or clinical/radiological diagnosis of aneoplasm , either primary (e.g.,
malignant glioma) or secondary (metastasis from systemic malignancy) with a history of
brain radiation therapy
- Completed fractionated radiation therapy (to 60 Gy for high grade gliomas) or
stereotactic radiosurgery or hypofractionated radiation therapy (e.g. for brain
metastases, anaplastic meningiomas), without or with concurrent chemotherapy
- New or increased enhancing brain lesion(s) OR nonenhancing brain lesion(s) if
receiving anti-angiogenic therapy, which is considered indeterminate for tumor
progression vs. radiation injury by the neuroradiologist or clinician
- Patient and/or guardian is able to provide written informed consent prior to study
- Age ≥ 18 years old
- Known allergic reaction to Gd-DTPA
- Any contraindication to gadolinium intravenous contrast as per standard Department of
Radiology contrast guidelines
- Any contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander).
- Pregnant or nursing female
- Unable to cooperate for MRI and/or PET/CT
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Memorial Sloan Kettering Cancer Center, New York, New York